Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) rose nearly 13%, and the rapid release of its core product, Senapali, was included in the Hang Seng Composite Index and is expected to open

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) rose nearly 13%. As of press release, it had risen 11.14% to HK$14.87, with a turnover of HK$5.1481 million.

According to the news, Yingpai Pharmaceutical announced this morning that the board of directors was informed by Cai Suixiong, the company's executive director and CEO, that it has recently purchased a total of 100,000 shares of the company's common shares on the open market. The average price of each share is about HK$14.6105, accounting for about 0.035% of the total number of shares issued by the company. Dr. Choi said he is confident about the Group's overall development prospects and potential growth. Furthermore, the company has been included as a constituent stock of the Hang Seng Composite Index. The relevant changes will be implemented after the market closes on September 4 and will take effect on September 7. The company's shares are expected to meet the criteria for inclusion in Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect transactions.

In the first half of this year, Yingpai Pharmaceutical achieved revenue of 105 million yuan, an increase of 316.8% year on year; net loss narrowed by 29.5% year on year. It is worth mentioning that since January 1 of this year, the core product senapalil was rapidly released after being included in the national medical insurance drug catalogue. In the first half of the year, sales revenue of senapalil in China reached 70.4 million yuan, an increase of 877.8% over the previous year. It has covered all provinces and nearly 1,200 medical institutions in the mainland.